D-0043-2025 Class II Ongoing

Recalled by Cipla USA, Inc. — Warren, NJ

FDA drug recall D-0043-2025 was initiated by Cipla USA, Inc. on Oct 23, 2024 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets. The recall status is ongoing. Affected quantity: 1,875 boxes (cipla and exlan).

Recall details

Product Type
Drugs
Report Date
Nov 20, 2024
Initiation Date
Oct 23, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,875 boxes (cipla and exlan)

Product description

Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98

Reason for recall

Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

Distribution pattern

USA nationwide.

Code information

Lot # NB240316, Exp 12/31/25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0043-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0043-2025. Report a data issue: hello@regdatalab.com.